Patent approved in the United States for Isofol’s drug candidate arfolitixorin
The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical Ingredient (arfolitixorin hemisulfate), the Drug Product and ready solution for treating cancer patients. The patent will be instrumental in supporting a future commercialization of arfolitixorin in the US market.The Merck patent US 10,059,710 is directed towards a stable formulation of [6R]-5,10-methylenetetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy. The advantageous stability characteristics of